pomalidomide has been researched along with HbS Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abdulmalik, O; Blobel, GA; Giardine, BM; Hardison, RC; Huang, P; Keller, CA; Khandros, E; Peslak, SA; Sharma, M; Zhang, Z | 1 |
| Al Abed, Y; Blanc, L; Chung, MC; Costa, FF; de Melo, TRF; de Souza, CM; Dos Santos, JL; Dulmovits, BM; Fernandes, GFDS; He, M; Lanaro, C | 1 |
| Al-Abed, Y; Allen, SL; An, X; Appiah-Kubi, AO; Blanc, L; Chan, KW; Didier, S; Dulmovits, BM; Gallagher, PG; Gould, M; Hale, J; He, M; Husain-Krautter, S; Lipton, JM; Liu, JM; Marambaud, P; Mohandas, N; Papoin, J; Singh, SA; Taylor, N; Vlachos, A | 1 |
| Corral, LG; Kutlar, A; Kutlar, F; Meiler, SE; Moutouh-de Parseval, LA; Swerdlow, PS; Wade, M; Xue, Y; Yerigenahally, SD | 1 |
| Brady, H; Chan, K; Corral, LG; De Parseval, LM; Ferguson, GD; Jensen-Pergakes, K; Jhaveri, U; Morris, CL; Richard, N; Verhelle, D; Wilkey, C; Xie, W | 1 |
| Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D | 1 |
6 other study(ies) available for pomalidomide and HbS Disease
| Article | Year |
|---|---|
Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.
Topics: Adult; Anemia, Sickle Cell; Cell Line; Cell Separation; Cells, Cultured; Erythroblasts; Erythroid Cells; Fetal Hemoglobin; Gene Expression Profiling; Hemoglobin A; Humans; Hydroxyurea; Proteomics; RNA, Messenger; Thalidomide | 2020 |
Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
Topics: Anemia, Sickle Cell; Dose-Response Relationship, Drug; Humans; Molecular Structure; Structure-Activity Relationship; Thalidomide | 2021 |
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.
Topics: Adult; Anemia, Sickle Cell; beta-Globins; Carrier Proteins; Erythroid Precursor Cells; Erythropoiesis; Fetal Hemoglobin; gamma-Globins; Gene Expression Regulation, Developmental; Genetic Vectors; Hematopoietic Stem Cells; Histone Demethylases; Humans; Ikaros Transcription Factor; Kruppel-Like Transcription Factors; Lentivirus; Multiple Myeloma; Neoplasm Proteins; Nuclear Proteins; Proteasome Endopeptidase Complex; Repressor Proteins; RNA Interference; RNA, Small Interfering; SOXD Transcription Factors; Thalidomide; Transcription, Genetic | 2016 |
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Disease Models, Animal; Erythropoiesis; Fetal Hemoglobin; Hydroxyurea; Mice; Mice, Knockout; Mice, Transgenic; Thalidomide | 2011 |
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Gene Expression; Humans; Immunologic Factors; Immunoprecipitation; Lipopolysaccharides; Membrane Proteins; Monocytes; Nitrobenzenes; Prostaglandins; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Thalidomide; Transcription, Genetic | 2007 |
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Cells, Cultured; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Synergism; Erythroid Cells; Erythropoiesis; Fetal Hemoglobin; Humans; Hydroxyurea; Lenalidomide; Models, Biological; Thalidomide; Up-Regulation | 2008 |